182 related articles for article (PubMed ID: 36825818)
1. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration.
Matsuda KM; Yoshizaki A; Kuzumi A; Toyama S; Awaji K; Miyake T; Sato S
Rheumatology (Oxford); 2023 Sep; 62(9):3139-3145. PubMed ID: 36825818
[TBL] [Abstract][Full Text] [Related]
2. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis.
Clark KE; Etomi O; Denton CP; Ong VH; Murray CD
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S168-70. PubMed ID: 26315822
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience.
Agostini E; De Luca G; Bruni C; Bartoli F; Tofani L; Campochiaro C; Pacini G; Moggi-Pignone A; Guiducci S; Bellando-Randone S; Shoenfeld Y; Dagna L; Matucci-Cerinic M
Autoimmun Rev; 2021 Dec; 20(12):102981. PubMed ID: 34718166
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulins in systemic sclerosis management. A large multicenter experience.
Tandaipan J; Guillén-Del-Castillo A; Simeón-Aznar CP; Carreira PE; De la Puente C; Narváez J; Lluch J; Rubio-Rivas M; Alegre-Sancho JJ; Bonilla G; Moriano C; Casafont-Sole I; García-Vicuña R; Ortiz-Santamaría V; Riera E; Atienza-Mateo B; Blanco R; Galisteo C; Gonzalez-Martin JJ; Pego-Reigosa JM; Pros A; Heredia S; Castellví I
Autoimmun Rev; 2023 Nov; 22(11):103441. PubMed ID: 37708984
[TBL] [Abstract][Full Text] [Related]
6. Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.
Matsuda KM; Sugimoto E; Ako Y; Kitamura M; Miyahara M; Kotani H; Norimatsu Y; Hisamoto T; Kuzumi A; Fukasawa T; Sato S; Yoshizaki A
J Dermatol; 2024 Jun; 51(6):741-751. PubMed ID: 38558171
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis.
Gomes JP; Santos L; Shoenfeld Y
Clin Immunol; 2019 Feb; 199():25-28. PubMed ID: 30543921
[TBL] [Abstract][Full Text] [Related]
8. Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review.
Koczanowski S; Morrisroe K; Fairley J; Nikpour M; Oon S; Brown Z
Semin Arthritis Rheum; 2024 Jun; 68():152471. PubMed ID: 38954999
[TBL] [Abstract][Full Text] [Related]
9. Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample.
Valenzuela A; Li S; Becker L; Fernandez-Becker N; Khanna D; Nguyen L; Chung L
Rheumatology (Oxford); 2016 Apr; 55(4):654-8. PubMed ID: 26615031
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of a refractory dysbiotic intestinal pseudo-obstruction in a patient with systemic sclerosis-polymyositis overlap syndrome by intravenous immunoglobulin administration possibly related to gut flora normalisation.
Kamei R; Yamaoka T; Ikinaga K; Murota H; Shimizu K; Katayama I
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):214-215. PubMed ID: 28229828
[No Abstract] [Full Text] [Related]
11. Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature.
Sanges S; Rivière S; Mekinian A; Martin T; Le Quellec A; Chatelus E; Lescoat A; Jego P; Cazalets C; Quéméneur T; Le Gouellec N; Senet P; Francès C; Deroux A; Imbert B; Fain O; Boukari L; Sené T; Deligny C; Mathian A; Agard C; Pugnet G; Speca S; Dubucquoi S; Hatron PY; Hachulla É; Launay D
Autoimmun Rev; 2017 Apr; 16(4):377-384. PubMed ID: 28232167
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis.
Dein E; Kuo PL; Hong YS; Hummers LK; Mecoli CA; McMahan ZH
Semin Arthritis Rheum; 2019 Dec; 49(3):405-410. PubMed ID: 31202479
[TBL] [Abstract][Full Text] [Related]
13. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality.
Richard N; Hudson M; Wang M; Gyger G; Proudman S; Stevens W; Nikpour M; ; ; Baron M
Rheumatology (Oxford); 2019 Apr; 58(4):636-644. PubMed ID: 30517716
[TBL] [Abstract][Full Text] [Related]
14. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
15. Dysbiosis and Gut Microbiota Modulation in Systemic Sclerosis.
Lemos MPC; Zucoloto TG; Oliveira MC; de Oliveira GLV
J Clin Rheumatol; 2022 Mar; 28(2):e568-e573. PubMed ID: 34030162
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome.
Nguyen AD; Andréasson K; McMahan ZH; Bukiri H; Howlett N; Lagishetty V; Lee SM; Jacobs JP; Volkmann ER
Semin Arthritis Rheum; 2023 Jun; 60():152185. PubMed ID: 36870237
[TBL] [Abstract][Full Text] [Related]
17. Mortality, recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction.
Mecoli C; Purohit S; Sandorfi N; Derk CT
J Rheumatol; 2014 Oct; 41(10):2049-54. PubMed ID: 25128517
[TBL] [Abstract][Full Text] [Related]
18. A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease.
Low AHL; Teng GG; Pettersson S; de Sessions PF; Ho EXP; Fan Q; Chu CW; Law AHN; Santosa A; Lim AYN; Wang YT; Haaland B; Thumboo J
Semin Arthritis Rheum; 2019 Dec; 49(3):411-419. PubMed ID: 31208714
[TBL] [Abstract][Full Text] [Related]
19. Comparing Clinical, Imaging, and Physiological Correlates of Intestinal Pseudo-Obstruction: Systemic Sclerosis vs Amyloidosis and Paraneoplastic Syndrome.
Pamarthy R; Berumen A; Breen-Lyles M; Grover M; Makol A
Clin Transl Gastroenterol; 2020 Aug; 11(8):e00206. PubMed ID: 32931184
[TBL] [Abstract][Full Text] [Related]
20. [Five cases of systemic sclerosis with associated with intestinal pseudo-obstruction].
Ishikawa M; Okada J; Kondo H
Ryumachi; 1999 Oct; 39(5):768-73. PubMed ID: 10614172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
